 | Up a level |
Regan, Meredith M; Neven, Patrick; Giobbie-Hurder, Anita; Goldhirsch, Aron; Ejlertsen, Bent; Mauriac, Louis; Forbes, John F; Smith, Ian; Láng, István; Wardley, Andrew; Rabaglio, Manuela; Price, Karen N; Gelber, Richard D; Coates, Alan S; Thürlimann, Beat; BIG 1-98 Collaborative Group, ; International Breast Cancer Study Group (IBCSG), (2011). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet oncology, 12(12), pp. 1101-8. Oxford: Elsevier 10.1016/S1470-2045(11)70270-4
Crivellari, Diana; Sun, Zhuoxin; Coates, Alan S; Price, Karen N; Thürlimann, Beat; Mouridsen, Henning; Mauriac, Louis; Forbes, John F; Paridaens, Robert J; Castiglione-Gertsch, Monica; Gelber, Richard D; Colleoni, Marco; Láng, István; Del Mastro, Lucia; Gladieff, Laurence; Rabaglio, Manuela; Smith, Ian E; Chirgwin, Jacquie H; Goldhirsch, Aron (2008). Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. Journal of clinical oncology, 26(12), pp. 1972-9. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2007.14.0459
Mouridsen, Henning; Keshaviah, Aparna; Coates, Alan S; Rabaglio, Manuela; Castiglione-Gertsch, Monica; Sun, Zhuoxin; Thürlimann, Beat; Mauriac, Louis; Forbes, John F; Paridaens, Robert; Gelber, Richard D; Colleoni, Marco; Smith, Ian; Price, Karen N; Goldhirsch, Aron (2007). Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. Journal of clinical oncology, 25(36), pp. 5715-22. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2007.12.1665
